Page last updated: 2024-12-06

6-hydroxybenzo(a)pyrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-Hydroxybenzo(a)pyrene (6-OHBaP) is a hydroxylated metabolite of benzo(a)pyrene, a known human carcinogen. It is formed in the body through the action of cytochrome P450 enzymes, which are involved in the detoxification of foreign compounds. 6-OHBaP is thought to be more reactive than benzo(a)pyrene and is therefore considered to be a more potent mutagen. It is a key intermediate in the metabolic activation of benzo(a)pyrene to carcinogenic metabolites. The synthesis of 6-OHBaP can be achieved via enzymatic oxidation of benzo(a)pyrene by cytochrome P450 enzymes or by chemical oxidation using oxidizing agents like potassium permanganate. Studies on 6-OHBaP are important due to its role in the carcinogenic process. It is used in research to understand the mechanisms of benzo(a)pyrene-induced carcinogenesis and to identify potential targets for cancer prevention and treatment. Research on 6-OHBaP has revealed its involvement in DNA adduct formation, which can lead to mutations and ultimately cancer. It has also been shown to induce oxidative stress and inflammation, contributing to the development of cancer. Understanding the biological effects of 6-OHBaP provides valuable insights into the mechanisms of cancer development and may lead to the development of novel strategies for cancer prevention and treatment.'
```

6-hydroxybenzo(a)pyrene: RN given refers to parent cpd; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36636
CHEMBL ID1908052
CHEBI ID34470
SCHEMBL ID3798629
MeSH IDM0080619

Synonyms (28)

Synonym
BIDD:ER0458
6-hydroxy benzo[a]pyrene
benzo[a]pyren-6-ol
6-hydroxybenzo[a]pyrene
33953-73-0
nsc-30998
5-hydroxy-3,4-benzopyrene
nsc30998
nsc 30998
6-hydroxybenzo(a)pyrene
benzo(a)pyren-6-ol
benzo(a)pyrene, 6-hydroxy-
brn 1982121
ccris 1072
benzo(a)pyrenol
benzo[b]pyren-6-ol
63455-19-6
unii-i68u5515ci
i68u5515ci ,
CHEMBL1908052
chebi:34470 ,
AKOS015906069
benzo(pqr)tetraphen-6-ol
hydroxybenzo(a)pyrene, 6-
SCHEMBL3798629
Q27116091
DTXSID30955534
benzo[pqr]tetraphen-6-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ortho- and peri-fused polycyclic arene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]